Navigation Links
Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
Date:11/20/2008

LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) will host a teleconference call today at 2:30 p.m. EST to review its drug development programs and financial results for the third quarter of 2008. Duska's chief executive officer, James S. Kuo, MD, MBA, will host the call and there will be a question-and-answer session immediately afterward.

To participate in the teleconference, please call toll-free 800.895.0198 (direct dial 785.424.1053) five minutes prior to the scheduled starting time in order to register for the call. A replay of the call will be available after its completion for ten days at 800.283.8217 (direct dial 402.220.0868).

"We have made remarkable progress in our two lead drug development programs this past quarter as we prepare for a Phase 2 trial for one compound and a Phase 3 trial for the other early next year," said Dr. Kuo. "In addition, we strengthened the intellectual property position around our ATPotent program through licenses with several inventors."

    Highlights of accomplishments included:

    -- Submission of a pivotal Phase 3 ATPace clinical trial protocol for
       review under a Special Protocol Assessment (SPA) procedure with the
       U.S. Food and Drug Administration (FDA).

       Subject to securing an agreement with the FDA, Duska intends to
       initiate a single, prospective, double-blind, placebo-controlled and
       randomized Phase 3 clinical trial with ATPace, its lead product. The
       trial will be aimed at demonstrating clinical safety and efficacy of
       ATPace in treating emergency room patients presenting with paroxysmal
       supraventricular tachycardia (PSVT).  PSVT is a condition characterized
       by a rapid, regular heart rate originating in the atria, which affects
       approximately 570,000 patients in the United States alone; in addition,
       89,000 new cases per 
'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
2. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
3. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
4. Duska Therapeutics Obtains Standard & Poors Listing
5. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
6. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
7. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
8. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
9. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
10. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
11. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... FAIRFIELD, Connecticut (PRWEB) October 31, 2014 ... remains sanitary is an uphill battle in many corners ... for a rural farming community in northwestern Bolivia where ... is where a group from Fairfield University’s School of ... at the Unidad Academica Campesina (UAC), “the united college ...
(Date:10/31/2014)... October 30, 2014 Two separate ... were hosted by Charm Sciences at its Andover, ... week in the US, the participants discussed international ... hygiene management, and process verification, and received hands-on ... This was the first visit to the United ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 This ... Global and China Biocides industry. The report provides ... and industry chain structure as well as industry ... including China’s domestic market as well as Global ... analysis. The report on the Chinese biocides ...
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
Breaking Biology Technology:Fairfield University School of Engineering project reduces illness in rural community 2Fairfield University School of Engineering project reduces illness in rural community 3Charm Sciences Hosts Executives from Latin America for Dairy Safety Executive Seminar 2Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 2Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3
... a world-wide leader in custom genomic and molecular ... position itself as the Next-Generation Sequencing Provider of ... attributed to the company,s ability to respond quickly ... genomics technologies. Building on this success, SeqWright announced ...
... that a new market research report is available in ... 1011 http://www.reportlinker.com/p0358381/Industrial-Biotechnology-China-News-1011.html ... not past." Owing to the monetary easing policy adopted ... affect almost all industries in China, including corn products. ...
... can be used to control the electrical properties ... devices and highly sensitive sensors. This year,s ... into graphene, recognising its potential for many applications ... technology. The UK,s National Physical Laboratory, along with ...
Cached Biology Technology:SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2Reportlinker Adds Industrial Biotechnology China News 1011 2New research shows how light can control electrical properties of graphene 2
(Date:10/31/2014)... Geologists are letting the air out of a nagging mystery ... have long speculated as to why animal species didn,t flourish ... to prosper at the end of the Proterozoic period, about ... stretch before that, when most researchers think there also was ... so great then, after all. , In a study published ...
(Date:10/31/2014)... uncovered key steps involved in programmed cell death, offering ... cancers and neurodegenerative diseases. , The research teams ... to discover the three-dimensional structure of a key cell ... in how it causes cell death. Their studies were ... Proceedings of the National Academy of Sciences ...
(Date:10/30/2014)... soil subsidence and reduce greenhouse gas emissions, according ... by Dartmouth College researchers and their colleagues. , ... to continually measure the fluctuations of both carbon ... in the journal by Global Change ... organic soils has resulted in vast soil subsidence ...
Breaking Biology News(10 mins):Lack of oxygen delayed the rise of animals on Earth 2A matter of life and death: Cell death proteins key to fighting disease 2Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2
... A deadly, rare type of soft-tissue cancer may be completely ... growth, UT Southwestern Medical Center researchers report. In the ... found that inhibiting the action of a protein called BRD4 ... malignant peripheral nerve sheath tumors (MPNSTs). "This study identifies ...
... international group of investigators has discovered new genes, pathways ... to rheumatoid arthritis (RA). The findings are published online ... association study (GWAS) meta-analysis in more than 100,000 people ... sites of genetic variation involved in risk for RA. ...
... of Excellence for Coral Reef Studies has been awarded $A28m ... Centre will be reorganised into three new research programs - ... Responding to a Changing World. , Centre Director, Professor Terry ... provide understanding of coral reefs and their interaction with ...
Cached Biology News:UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer 2Researchers complete a milestone in defining the genetic basis of rheumatoid arthritis 2
... A full-featured high-performance ICP-MS system designed for ... interface, Omega II off-axis ion lens, true ... 7500a can handle the widest range of ... the 7500a now includes as standard Agilents ...
... Identical to the DH-2000, except that it ... 190-1700 nm wavelength range and comes with a ... up to 5 Hz) The DH-2000 ... spectrum of deuterium and tungsten halogen light sources ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... handy dispensers save space and organize ... other garb. They are the perfect ... used in labs, processing and manufacturing. ... and the particles they attract. Many ...
Biology Products: